JP Morgan 2024 – Frank Gleeson
In this brief dispatch from JP Morgan, editor-in-chief Jonah Comstock grabs a few minutes with Frank Gleeson, CEO of Satellos Bioscience.
Gleeson talks about Satellos’s mission to create a pill to regenerate muscle tissue in people with Duchenne muscular dystrophy. He discusses the drug candidate, the latest data, and the company’s strategic plans.
They also discuss trends at the conference more broadly and why there’s reason for optimism this year – or any year. Finally, they conclude with a conversation about the importance of keeping the patient at the centre of these discussions.
Check out the full interview with an interesting biotech entrepreneur below.